Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
<h4>Background</h4> <p>Patients with type 2 diabetes mellitus (T2DM) have elevated cardiovascular risk. PCSK9 monoclonal antibodies have been shown to reduce LDL-C and other lipids, but specific efficacy for patients with diabetes is unknown.</p> <h4>Methods</h4>...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Elsevier
2016
|